The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Company's Spinal Cord Stimulation System Approved in Australia

Sept. 19, 2018 - Nevro Corp.'s Senza II spinal cord stimulation system has received approval in Australia from the Therapeutic Goods Administration. (Neuro News)

Company Begins Clinical Trial of Vagus Nerve Stimulation in Heart Failure

Sept. 18, 2018 - LivaNova announced it has launched a pivotal study of its vagus nerve stimulation device for heart failure, with the first implant completed in Iowa. The multi-center Anthem-HFrEF study will have up to 800 participants through the year 2022. They will be randomized 2:1 to receive the implant or standard medical care. (Mass Device)

Medical Center's New $20 Million Grant Will Help Fund Research Into Brain Stimulation to Treat Depression

Sept. 18, 2018 - The University of California, San Francisco has received a $20 million grant from the family of audio pioneer Ray Dolby. With this funding, the medical center will seek to start a brain-stimulation clinical trial in 2019. Using a network of electrodes on the surface of the brain, the study will investigate identifying and targeting dysfunctional brain circuits to treat depression. (The Mercury News)

Report: Epidural Spine Stimulation Improved Blood Pressure and Heart Rate Regulation in Spine Injury Patients

Sept. 17, 2018 - Research at the University of Louisville's Kentucky Spinal Cord injury Research Center, published in JAMA Neurology, described improvements four spine-injured patients experienced in blood pressure and heart rate regulation, after receiving spinal cord epidural stimulation. (EurekAlert)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM